



Pathogenesis and Novel Therapeutics in Asthma Volume II

Guest Editor:

Dr. Stanislaw Bazan-Socha

Department of Internal Medicine,
Jagiellonian University Medical
College, 30-688 Kraków,
Małopolskie, Poland

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Asthma is a prevalent chronic inflammatory disease of the airways with complex etiology, mechanistic pathways, and variable clinical presentation. Such heterogeneity renders the search for targeted therapies. Currently, the best-known disease phenotype with tailored biological treatment is eosinophilic asthma. However, even in some of these patients, anti-IL5 treatment is ineffective. Furthermore, about a quarter of patients, especially those with a severe phenotype, develop progressive and irreversible airway obstruction, leading to persistent symptoms despite optimized treatment. Therefore, new therapeutic approaches are still needed, particularly in severe asthma. The Special Issue focuses on asthma research referring to modern personalized therapeutic opportunities. Particular interest is directed to novel asthma biomarkers, including molecular and epigenetic ones, providing new light on pathogenesis, phenotyping, and customized therapy in various airway inflammatory patterns of that disease. In addition, research articles on airway epithelial cell dysfunction, airway remodeling, and the overlap between asthma and chronic obstructive pulmonary disease are welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)